Document Detail


Direct-acting antiviral medications for chronic hepatitis C virus infection.
MedLine Citation:
PMID:  21528041     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. Current standard therapy consists of pegylated interferon α and ribavirin, both of which have nonspecific and largely unknown mechanisms of action. New therapies are in development that act directly on the hepatitis C virus at various points in the viral life cycle. Published clinical trial data on these therapies are summarized in this paper. A new era of hepatitis C virus treatment is beginning, the ultimate goals of which will be directly targeting the virus, shortening the length of therapy, improving sustained virologic response rates, and minimizing side effects.
Authors:
Alison B Jazwinski; Andrew J Muir
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Gastroenterology & hepatology     Volume:  7     ISSN:  1554-7914     ISO Abbreviation:  Gastroenterol Hepatol (N Y)     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-04-29     Completed Date:  2011-07-14     Revised Date:  2014-10-16    
Medline Journal Info:
Nlm Unique ID:  101262648     Medline TA:  Gastroenterol Hepatol (N Y)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  154-62     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intraoral epithelioid hemangioendothelioma: an intermediate vascular tumor- a case report.
Next Document:  Crohn's disease: the first visit.